Saye Z N, Forget P P, Geubelle F
Pediatr Pulmonol. 1987 Jan-Feb;3(1):8-12. doi: 10.1002/ppul.1950030105.
Fourteen patients with chronic bronchopulmonary disease and suspected of having gastroesophageal reflux were studied for 16 hr by intraesophageal pH monitoring to investigate the effect of the prokinetic drug cisapride. Cisapride was administered orally in a double-blind cross-over study. The initial dose was 0.3 mg/kg, followed by 0.15 mg/kg every 4 hr for 12 hr. Cisapride was shown to be superior to placebo in reducing gastroesophageal reflux. Both during the total recording period and during the sleep period, cisapride significantly decreased the percentage of time during which the pH was 4 or less (vs placebo; total period, -60%; sleep, -80%) and reduced the number of reflux spells of at least 5 min (-64%; -92%). No adverse effects of cisapride were observed.
对14例慢性支气管肺疾病且疑似患有胃食管反流的患者进行了16小时的食管内pH监测，以研究促动力药物西沙必利的作用。在一项双盲交叉研究中口服给予西沙必利。初始剂量为0.3mg/kg，随后每4小时给予0.15mg/kg，共12小时。结果显示，西沙必利在减少胃食管反流方面优于安慰剂。在整个记录期和睡眠期，西沙必利均显著降低了pH值小于或等于4的时间百分比（与安慰剂相比；整个记录期，降低60%；睡眠期，降低80%），并减少了至少持续5分钟的反流发作次数（分别降低64%和92%）。未观察到西沙必利的不良反应。
